Abstract: This invention provides methods for specifically testing ulcerative colitis and primary sclerosing cholangitis. The first aspect of the invention provides a method for testing ulcerative colitis comprising a step of detection comprising detecting, as an indicator of ulcerative colitis, an antibody immunologically reacting with integrin ?V?6 and/or an antibody immunologically reacting with integrin ?V?3 in a specimen. The second aspect of the invention provides a method for testing primary sclerosing cholangitis comprising a step of detection comprising detecting, as an indicator of primary sclerosing cholangitis, an antibody immunologically reacting with integrin ?V?6 and/or an antibody immunologically reacting with integrin ?V?3 in a specimen.

Abstract: Provided is a cancer development risk assessment device (1) capable of determining the possibility of cancer development in a subject to be assessed in short time. The cancer development risk assessment device (1) includes a measurement unit (3) and a controller (4). The measurement unit (3) is configured to measure concentrations of a plurality of types of target components included in exhaled air collected from a subject to be assessed. The controller (4) is configured to calculate an assessment score correlated to the possibility of cancer being developed in the subject to be assessed based on measurement results of the concentrations obtained by the measurement unit (3).